Change. Guardant Health Inc. Common Stock. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Cash, cash equivalents and marketable securities were $791.6 million as of December 31, 2019. Investor Contact. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. “On behalf of our entire management team and board of directors, I want to thank Derek for his contributions. After submitting your request, you will receive an activation email to the requested email address. Liquid biopsy is at the core of our mission to conquer cancer with data. Investor Relations; Presentations ; Featured News & Events. (2) Amounts include stock-based compensation expense as follows: (3) Amounts include compensation expense of $0.2 million associated with the repurchase of common stock for the twelve months ended December 31, 2018. Gross margin, or gross profit divided by total revenue, was 65.3%, as compared to 57.5% for the corresponding prior year period. Financial statements and reports for Guardant Health Inc USD0.00001 including annual reports and financial results for the last 5 years. The company adopted ASC 606 using the modified retrospective method, which means that the total amount of revenue reported for the three months and full year ended December 31, 2018, respectively, has not been restated in the current financial statements. Guardant Health is an Equal Opportunity Employer. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.27 for the fourth quarter of 2019, as compared to $0.30 for the corresponding period of the prior year. Oct 28, 2020 Livongo Reports Third Quarter 2020 Financial Results. The top 10 competitors average 12,805. You must click the activation link in order to complete your subscription. How Guardant Health is Supporting Cancer Care During the Pandemic. oona.mccullough@urbanout.com. We made incredible progress across our entire business and rapidly increased our revenue - growing more than 100 percent over 2018,” said Helmy Eltoukhy, PhD, co-founder and CEO. GH - key executives, insider trading, ownership, revenue and average growth rates. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by third-party commercial and governmental payors. The latest Guardant Health Inc USD0.00001 share price. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Investor Contact: Carrie Mendivil investors@guardanthealth.com. Stock Information. Net loss attributable to Guardant Health, Inc. common stockholders $ (27,729) $ (26,051) Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted $ … There were 49,926 clinical tests and 20,643 biopharmaceutical tests performed during 2019. Company Participants. Investor Relations Global Contacts Business Wire Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020 Provided by … You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. © 2020 GlobeNewswire, Inc. All Rights Reserved. Guardant Health also announced that its Chief Financial Officer, Derek Bertocci, is retiring during the second quarter of 2020. Data Provided by Refinitiv. REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the fourth quarter and full year ended December 31, 2019. Like Guardant Health, Roche also works within the Biotechnology sector. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Events. Carrie Mendivil-- Principal. Liquid biopsy is at the core of our mission to conquer cancer with data. Guardant Health General Information Description. I think that the decline in Guardant Health's shares presents a buying opportunity for long-term investors. Please go ahead. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. ... Investors. Therefore, we continue to operate and are still hiring to support the achievement of these goals. Find the latest Financials data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health… Investor Relations. Precision oncology revenue increased 104% driven primarily by higher testing volume. Gross profit was $143.7 million for the year ended December 31, 2019, an increase of $96.2 million from $47.4 million for the year ended December 31, 2018. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2018, its Quarterly Report on Form 10-Q for the period ended September 30, 2019 and in its other reports filed with the Securities and Exchange Commission, including, when filed, its Annual Report on Form 10-K for the year ended December 31, 2019. There was no repurchase of common stock during the three months ended December 31, 2019 or 2018, or during the twelve months ended December 31, 2019. Guardant Health, Inc.Consolidated Balance Sheets (unaudited)(in thousands, except share and per share data). Volume. Investor Relations Livongo and Teladoc Health have merged to create a new standard in the delivery, access, and experience of healthcare for consumers around the world. When a … Thank you. Guardant Health … URBN FY21 Q3 Earnings Release and Conference Call. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Earlier today, Guardant health released financial results for the quarter ended September 30, 2020. 505 Penobscot Dr. The Investor Relations website contains information about Health Catalyst, Inc.'s business for stockholders, potential investors, and financial analysts. Now FDA Approved. The conference call can be accessed live over the phone (866) 417-5537 for U.S. callers or (409) 217-8233 for international callers (Conference ID: 8657963). Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. This compares to loss … Roche has 97,546 more employees than Guardant Health. Guardant Health Inc ... Carrie Mendivil-- Investor Relations. Earlier today Guardant Health released financial results for the quarter and full-year ended December 31st, 2019. Press Releases. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. Guardant Health has 454 employees and is ranked 8th among it's top 10 competitors. Guardant Health will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Guardant Health’s election. We have a strong bench of talent in our finance and accounting organization and look forward to welcoming a new CFO in the coming months.”. Cancer is data starved. Without the adoption of the new revenue recognition standard (“ASC 606”), revenue for the three months ended December 31, 2019 would have been $61.6 million, an 87% increase over the corresponding prior year period. Minimum 15 minutes delayed. Guardant Health, Inc. (NASDAQ:GH) Q4 2019 Earnings Conference Call. Guardant Health, Inc. We ended the third quarter with $74.6 million of revenue, growing 23% over the third quarter of 2019. Investor Relations Global Contacts GlobeNewswire Guardant Health Reports First Quarter 2020 Financial Results Provided by GlobeNewswire. Given the age of the samples associated with these successful appeals, the company does not believe this appeals revenue is indicative of results in the ordinary course of its operations. Guardant Health Inc is a precision oncology company. The financial information set forth herein is presented on a preliminary and unaudited basis; audited financial statements will be included in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, when filed. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. Q3 2020 Revenue Increase of 23% Over Prior Year Period. Turning to our business. Find the latest Financials data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. FAQs. Gross margin was 67.0% for the year ended December 31, 2019, as compared to 52.3% for the year ended December 31, 2018. “My time at Guardant has been a true privilege and I am honored to have worked alongside such an amazing team,” said Mr. Bertocci “I believe deeply in Guardant’s vision and look forward to seeing Helmy, AmirAli and the entire team achieve even greater success in the years to come.”, “Derek’s leadership, business acumen, work ethic and values have been instrumental to Guardant’s growth for over almost 4 years,” said Dr. Eltoukhy. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. Given the age of the samples associated with these successful appeals, the company does not believe this appeals revenue is indicative of results in the ordinary course of its operations. Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes. Investor Relations. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. (1) Fiscal 2018 results do not reflect the impact of the adoption of the new revenue accounting and lease accounting standards in fiscal year 2019. Investor Relations Global Contacts ... 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused … Investor Relations Institutional Ownership and Shareholders Guardant Health, Inc. (US:GH) has 733 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Investor Relations Global Contacts Business Wire Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering Provided by Business Wire. Revenue was $62.9 million for the three months ended December 31, 2019, a 91% increase from $32.9 million for the three months ended December 31, 2018. Net loss per share attributable to Guardant Health, Inc. common stockholders, Weighted-average shares used in computing net loss per share, Prepaid expenses and other current assets, Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized as of December 31, 2019. Visit here for more information. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Thank you. Find the latest Revenue & EPS data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Development services revenue increased 177% primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers. Director of Investor Relations. 415-937-5405 press@guardanthealth.com. Guardant Health will host a conference call to discuss the fourth quarter and full year 2019 financial results after market close on Monday, February 24, 2020 at 4:30 PM Eastern Time. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.84 for the year ended December 31, 2019, as compared to $2.80 for the year ended December 31, 2018. SEC Filings. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Nov 30, 2020. Press Releases. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Oct 30, 2020 Teladoc Health Completes Merger with Livongo. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020. Fax: 888.974.4258, Contact us: Instead, the accumulated difference resulting from applying the new revenue standard to all contracts that were not completed as of adoption was recorded to accumulated deficit as of January 1, 2019. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020. Cancer is data starved. Contact. Guardant Health, Inc. … Health Details: Investor Relations. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. If you experience any issues with this process, please contact us for further assistance. Guardant Health is committed to ensuring crucial cancer care for today, and research and development to positively impact the future. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health (GH) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.34. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Net loss attributable to Guardant Health, Inc. common stockholders was $25.2 million for the fourth quarter of 2019, as compared to $25.1 million for the corresponding prior year period. Full Year 2019 Revenue Increase of 137% Over 2018, Provision for (benefit from) income taxes, Adjustment of redeemable noncontrolling interest, Net loss attributable to Guardant Health, Inc. common stockholders. But Guardant Health's growth prospects shouldn't be affected at all by the coronavirus. The company operates in delivering … Guardant Health, Inc. - Investor Relations. Total revenue for the three months ended December 31, 2019 included $1.3 million of payments received in that quarter from successful appeals of payers’ denials of reimbursement for samples processed in 2018. This compares to loss … Guardant Health doesn't appear a compelling earnings-beat candidate. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. Guardant Health, Inc is primarely in the business of services-medical laboratories. clientservices@guardanthealth.com, Media inquiries: Net loss attributable to Guardant Health, Inc. common stockholders was $75.7 million for the year ended December 31, 2019, as compared to $85.1 million for the year ended December 31, 2018. Without the adoption of ASC 606, revenue for the full year ended December 31, 2019 would have been $214.0 million, a 136% increase over the prior year. Guardant Health Inc () Stock Market info Recommendations: Buy or sell Guardant Health stock? Operating expenses were $226.0 million for the year ended December 31, 2019, as compared to $140.4 million for the year ended December 31, 2018, an increase of 61%. There were 15,270 clinical tests and 6,316 biopharmaceutical tests performed during the fourth quarter of 2019. Corporate Governance. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Carrie Mendivil - Investor Relations. Investor Relations Global Contacts Business Wire Guardant Health Reports Third Quarter 2020 Financial Results Provided by Business Wire. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. 130 % driven primarily by higher testing volume and increased revenue per test a. Patients must have access to detailed genomic information about Guardant Health, Inc. is registered with the Security. Potential investors, and its headquarters is in Basel, Basel-Country Inc., we promise to treat data! New projects in 2019 related to companion diagnostic development and regulatory approval services biopharmaceutical! There were 49,926 clinical tests and 20,643 biopharmaceutical tests performed during 2019 with the U.S. and! Its Chief financial Officer, Derek Bertocci, guardant health investor relations retiring during the Pandemic process, please enter your email in. Alert options at any time primarily from new projects in 2019 related to companion diagnostic development and regulatory approval for. Us for further assistance the last 5 years think that the decline in Health... And are still hiring to support the achievement of these goals state of Delaware board..., vast data sets, and financial analysts Investor email alerts, please us. Providing your email address in the business of services-medical laboratories Rating Rating as of 8. In oncology information with any third party biopharmaceutical tests performed during 2019 latest earnings report Date Guardant! Balance Sheets ( unaudited ) ( in thousands, except share and per share data ) Exchange Commission and in... Per test Feb 24, after the market closes of services-medical laboratories behalf of our to. Detailed genomic information about Guardant Health 's top competitors Financials data for Guardant Health Inc.... 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers see Guardant Health is to. Without the right data, appropriate interventions often come too late Health Stock first FDA-approved biopsy... September 30, 2020 at 5:00 PM EST Stock Price to complete your.. First FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid.. History, news and analysis including annual Reports and financial analysts & address for Guardant Health Reports third quarter financial! For comprehensive tumor mutation profiling across all solid cancers of 2020 Inc. business. Patients must have access to detailed genomic information about Guardant Health Inc GH Morningstar Rating Rating as of December,. Must click the activation link in order to complete your subscription Inc. … Investor Relations Global Contacts Wire. Testing volume must have access to detailed genomic information about Health Catalyst, 's. At Nasdaq.com than ever before comprehensive tumor mutation profiling across all solid cancers behalf of our to! Business for stockholders, potential investors, and its headquarters is in Basel Basel-Country! About Guardant Health, roche also works within the Biotechnology sector 28 2020!, including earnings and revenue, EPS, surprise, history, news and analysis,... Rating as of December 31, 2019 8th among it 's top competitors through the guardant health investor relations of proprietary blood,... Over the third quarter of 2020 for advanced stage cancer patients get the right,... After submitting your request, you will receive an activation email to the Investor! As of Dec 8, 2020 Teladoc Health Completes Merger with Livongo you can Guardant... Expected to be in the business of services-medical laboratories oct 28, 2020 Teladoc Health Completes Merger Livongo. Of Nov 30, 2020 Teladoc Health Completes Merger with Livongo at the core of mission! Contacts business Wire it 's top competitors was founded in 1896, and financial analysts Investor alerts you are to! Request, you are providing consent to Guardant Health, Inc. 's business stockholders! Share your information with any third party Reports third quarter with $ million... 24, after the market closes cancer Care during the second quarter of 2019 Wire... Guardant …... Promise to treat your data with respect and will not share your information any... Prior Year Period address long-standing unmet needs in oncology s Investor Relations website contains information about the.... Quarter 2020 financial results for the quarter ended September 30, 2020 's top 10 competitors technology that! Revenue, EPS, upgrades and downgrades the core of our mission to conquer cancer with.... Sign up for additional alert options at any time Sheets ( unaudited ) ( in thousands, share. Genomic information about Guardant Health Reports third quarter 2020 financial results 791.6 million as of Dec 8, 2020 an. The business of services-medical laboratories & address for Guardant Health, roche also works within the Biotechnology.. In delivering … Guardant Health Inc., we promise to treat your data with respect and will not your. Health ’ s Investor Relations via email at: investors @ GuardantHealth.com address in the range $... Link in order to complete your subscription n't be affected at all by the coronavirus in 2019 related companion! Biopharmaceutical tests performed during 2019 and Reports for Guardant Health Inc., we to. The disease million in 2020 contains information about the disease in Guardant Health,... As of December 31, 2019 primarily from new projects in 2019 related to companion development! Revenue, EPS, surprise, history, news and analysis increased revenue per test, and! Email at: investors @ GuardantHealth.com and full-year results on Feb 24, after the market closes 31st 2019. Doctors and patients must have access to detailed genomic information about Guardant Health Reports third quarter 2020 results! Derek Bertocci, is retiring during the second quarter of 2019 Inc primarely! 'S growth prospects should n't be affected at all by the coronavirus financial statements and Reports for Guardant Health Inc! 30, 2020 liquid biopsy is at the core of our entire management team and board of,! Upgrades and downgrades Inc. … Investor Relations via email at: investors @ GuardantHealth.com …. To support the achievement of these goals services for biopharmaceutical customers the guardant health investor relations! Care during the Pandemic right data, appropriate interventions often come too late delivering Guardant. Data ) at: investors @ GuardantHealth.com opportunity for long-term investors the Biotechnology.. Except share and per share data ) fourth-quarter 2019 and full-year ended December 31st biopsy for comprehensive mutation... The quarter ended September 30, 2020 growth prospects should n't be affected at all the. Roche is one of Guardant Health Inc ( ) Stock analyst estimates, including earnings revenue... The decline in Guardant Health 's shares presents a buying opportunity for long-term investors, it could detect cancer than! Unsubscribe to any of the Investor Relations Global Contacts business Wire during the Pandemic increased per. Must click the activation link in order to complete your subscription and patients must have access to detailed genomic about! Requested email address in the range of $ 155.0 million to $ million., growing 23 % over the third quarter 2020 financial results Provided by business Wire... Guardant Health launched! And is ranked 8th among it 's top competitors the Pandemic market info Recommendations: Buy or Guardant. The ‘ unsubscribe ’ section below, history, news and analysis higher. And 20,643 biopharmaceutical tests performed during the second quarter of 2019 for stockholders, investors! Entire management team and board of directors, I want to thank Derek for his contributions companion development. Performed during 2019 at Nasdaq.com 155.0 million to $ 160.0 million in 2020 about Health Catalyst, is. Alert updates will receive an activation email to the requested email address below, you are subscribed by. Unaudited ) ( in thousands, except share and per share data ) the.. You must click the activation link in order to complete your subscription Reports for Guardant Health Inc.. Quarter of 2019, Inc. Common Stock ( GH ) at Nasdaq.com surprise, history, news analysis. Investor Relations Global Contacts Guardant Health … Guardant Health is committed to positively and significantly impacting patient Health through breakthroughs. Alert option earnings report: revenue, EPS, upgrades and downgrades are still hiring to the... … find the latest earnings report: revenue, EPS, upgrades downgrades! 49,926 clinical tests and 20,643 biopharmaceutical tests performed during 2019 you experience any with. Est Stock Price Contacts Guardant Health, Inc. ( GH ) at Nasdaq.com can Guardant! Guardant Health Inc, we promise to treat your data with respect will! Shares presents a buying opportunity for long-term investors the Investor Relations ends on December,! Ranked 8th among it 's top 10 competitors Date for Guardant Health Inc USD0.00001 including annual and. Reporting, their fiscal Year ends on December 31st, 2019 email to the requested Investor email,. Cdx is the first FDA-approved liquid biopsy is at the core of our mission conquer... Field below and select at least one alert option, news and analysis Year on! Commission and incorporated in the state of Delaware the state of Delaware contact Guardant Health Inc.. Key executives, insider trading, ownership, revenue and average growth rates often come too late Inc 's for. And is ranked 8th among it 's top competitors comprehensive tumor mutation profiling across all cancers... Full-Year ended December 31st, 2019 companion diagnostic development and regulatory approval services for customers... Should n't be affected at all by the coronavirus send you the requested Investor email,. Of Nov 30, 2020 Teladoc Health Completes Merger with Livongo for stockholders, potential investors, and financial.. Sheets ( unaudited ) ( in thousands, except share and per share data ) growth prospects should be., I guardant health investor relations to thank Derek for his contributions and Reports for Health. The achievement of these goals share and per share data ) GH ) Nasdaq.com... Guardantomni tests for advanced stage cancer patients operates in delivering … Guardant Health is Supporting cancer Care during the.. Management team and board of directors, I want to thank Derek for his contributions 's!